Core Viewpoint - Kingsray Biotechnology (01548) reported a significant increase in revenue and a reduction in losses for the six months ending June 30, 2025, indicating strong operational performance and strategic investments in innovation and marketing [1] Financial Performance - Revenue from continuing operations reached $519 million, an increase of 81.92% year-on-year [1] - Loss attributable to equity holders narrowed to $25.462 million, a reduction of 85.46% year-on-year [1] - Basic loss per share was 1.18 cents [1] Segment Performance - Revenue from life sciences services and products was approximately $248 million, up 11.3% from about $222 million in the previous period [1] - Adjusted gross profit was approximately $126 million, an increase of 5.3% from about $120 million [1] - Adjusted gross margin slightly decreased from 53.9% to 51.0% [1] - Adjusted operating profit decreased slightly from approximately $47.8 million to about $46.4 million [1] Growth Drivers - Revenue and adjusted gross profit growth were primarily driven by: - Platform innovation and automation upgrades, particularly in protein and gene editing platforms, leading to reliable, fast, and high-quality service and product delivery [1] - Enhanced operational efficiency at production bases in mainland China, Singapore, and the United States [1] - Targeted activities and brand revitalization efforts to improve customer engagement [1] - The decrease in adjusted operating profit was attributed to increased investments in marketing transformation and research and development activities aimed at building long-term competitiveness [1]

Core Viewpoint - Kingsoft Biotech (01548) reported a significant increase in revenue and a reduction in losses for the six months ending June 30, 2025, indicating strong operational performance and strategic investments in innovation and marketing [1] Financial Performance - Revenue from continuing operations reached $519 million, a year-on-year increase of 81.92% [1] - Loss attributable to equity holders of the parent company narrowed to $25.462 million, a reduction of 85.46% year-on-year [1] - Basic loss per share was 1.18 cents [1] Segment Performance - Revenue from life sciences services and products was approximately $248 million, up 11.3% from about $222 million in the previous period [1] - Adjusted gross profit was around $126 million, an increase of 5.3% from approximately $120 million [1] - Adjusted gross margin slightly decreased from 53.9% to 51.0% [1] - Adjusted operating profit decreased from about $47.8 million to approximately $46.4 million [1] Growth Drivers - Revenue and adjusted gross profit growth were primarily driven by: - Platform innovation and automation upgrades, particularly in protein and gene editing platforms, leading to reliable, fast, and high-quality service and product delivery [1] - Enhanced operational efficiency at production bases in mainland China, Singapore, and the United States [1] - Targeted activities and brand revitalization efforts to improve customer engagement [1] - The decrease in adjusted operating profit was attributed to increased investments in marketing transformation and research and development activities aimed at building long-term competitiveness [1]

Core Viewpoint - China Biotechnology Services (08037) expects a significant reduction in losses for the first half of 2025, projecting a loss attributable to shareholders of no more than HKD 33 million, which is approximately 59% lower than the loss of HKD 79.917 million in the same period of 2024 [1] Group 1 - The improvement in operational performance is primarily attributed to successful cost control measures implemented by the company [1] - The company has experienced an increase in gross margin and a reduction in administrative expenses [1] - The company received compensation income of approximately HKD 14 million from insurance claims related to damages caused by heavy rainfall to construction sites in Hainan during 2024 [1]

Group 1 - The company expects a significant reduction in loss for the first half of 2025, with an estimated loss not exceeding 33 million HKD, compared to a loss of 79.917 million HKD in the same period of 2024, representing a decrease of approximately 59% [1] - The improvement in operational performance is primarily attributed to successful cost control measures, which have led to an increase in gross margin and a reduction in administrative expenses [1] - The company also received compensation income of approximately 14 million HKD from insurance claims related to damages caused by heavy rainfall to construction sites in Hainan during 2024 [1]

Group 1: Company Product Structure - The company operates as a one-stop service provider in life sciences, offering reagents, consumables, instruments, and laboratory services, integrating both well-known domestic and international brands as well as its own brands [1] - In 2024, the revenue from the company's own brands increased by nearly 30% year-on-year, indicating a strong growth trend [1] Group 2: Own Brand Performance - The overall gross margin for the company's own brands is approximately 50% [1] - The revenue share from own brands is currently low, but it is expected to increase as the company invests more resources into sales and continues to enrich its product pipeline [1] Group 3: Shareholder Incentives - In 2024, the company initiated a share repurchase plan, utilizing a total of 25,987,076 CNY to repurchase 927,600 shares, which will be used for equity incentives or employee stock ownership plans [1] - Future equity incentive or employee stock ownership plans will be introduced based on business development needs [1] Group 4: Overseas Market Expansion - The company's business is primarily focused on the domestic market, but it plans to accelerate the internationalization of its own brand products based on R&D and domestic sales performance [2] - In 2024, the company established a subsidiary in Singapore to facilitate overseas expansion [2] - The company is actively enhancing product visibility through online promotions and participation in offline exhibitions to further accelerate overseas market development [2] Group 5: M&A Strategy - The company aims to strengthen channel capabilities and R&D capabilities to better serve customers and provide a diverse range of products and services [2] - In terms of external growth, the company will seek potential upstream and downstream acquisition targets that align with its existing business, particularly in antibody-related applications [2]

Core Viewpoint - The company has announced a cash dividend distribution plan for the fiscal year 2024, with a total cash dividend of 19,719,985.64 yuan to be distributed to shareholders based on the adjusted total share capital after excluding repurchased shares [1][2][4]. Summary by Sections Dividend Distribution Plan - The company will distribute a cash dividend of 2.3 yuan per 10 shares (including tax) to all shareholders, with no stock dividends or capital reserve transfers [2][3]. - The total share capital for the distribution is calculated as 85,739,068 shares, after excluding 927,600 shares held in the repurchase account [1][2]. Calculation of Dividend Amount - The actual cash dividend amount is calculated as 19,719,985.64 yuan, which is derived from the formula: total cash dividend / total share capital * 10 = (19,719,985.64 / 86,666,668) * 10 = 2.275382 yuan per 10 shares [1][4]. - The reference price for ex-dividend trading will be adjusted by subtracting the per-share cash dividend amount from the closing price on the last trading day before the ex-dividend date [1][4]. Shareholder Eligibility and Taxation - The dividend distribution is applicable to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shenzhen Branch as of May 21, 2025 [3]. - Different tax rates will apply for various categories of shareholders, with specific provisions for foreign institutional investors and individual shareholders holding pre-IPO restricted shares [2][3]. Additional Information - The company has committed to adjusting the share price for any future reductions due to dividend distributions, ensuring compliance with relevant regulations [5]. - The company has provided contact information for inquiries regarding the dividend distribution [5].